About effector therapeutics inc - EFTR
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Foxborough, MA.
EFTR At a Glance
eFFECTOR Therapeutics, Inc.
124 Washington Street
Foxborough, Massachusetts 02035
| Phone | 1-508-543-1720 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -35,811,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
EFTR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.789 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.73 |
EFTR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,557,928.571 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
EFTR Liquidity
| Current Ratio | 0.769 |
| Quick Ratio | 0.769 |
| Cash Ratio | 0.712 |
EFTR Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -144.338 |
| Return on Equity | N/A |
| Return on Total Capital | -262.352 |
| Return on Invested Capital | N/A |
EFTR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 142.454 |
| Total Debt to Total Assets | 94.651 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |